Loading...
•
Mar 31
Viking Therapeutics Q1 2025 Earnings Report
Viking Therapeutics reported a net loss and no revenue in Q1 2025, while advancing its VK2735 programs and maintaining a strong cash position.
Key Takeaways
Viking Therapeutics posted a net loss in Q1 2025 with no revenues recorded, driven by increased R&D and G&A expenses. The company highlighted significant progress in its VK2735 development programs and maintained a robust cash balance of $852 million.
Net loss increased to $45.6 million due to higher R&D and G&A expenses.
No revenue was reported for the quarter.
Phase 3 trials for VK2735 (injectable) to begin in Q2 2025; oral trial fully enrolled.
Ended the quarter with $852 million in cash and investments.
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking Therapeutics expects continued advancement of VK2735 with Phase 3 trials and key data readouts in 2H25.
Positive Outlook
- Phase 3 trials of injectable VK2735 expected to begin in Q2 2025.
- VENTURE-Oral Dosing trial fully enrolled with data expected in 2H25.
- Broad manufacturing deal with CordenPharma to support commercialization.
- Strong cash position allows continued investment in pipeline.
- Encouraging safety and efficacy data from Phase 1 and 2 studies of VK2735.
Challenges Ahead
- No revenue generated in the quarter.
- Net loss widened from prior year due to higher expenses.
- R&D costs increased significantly from Q1 2024.
- G&A expenses also rose due to legal and insurance costs.
- No guidance on timing for potential product approvals.